ARTguide
Commercial- Indications
- Endometriosis
Company intelligence / Profile preview
Predictive Technology Group developed molecular diagnostic tests for infertility/endometriosis and marketed regenerative human cell/tissue products. It commercialized several genetic tests such as ARTguide™ and FertilityDX™. The company also offered regenerative medicine products like AmnioCyte™. It had a research collaboration with Atrin Pharmaceuticals on cancer diagnostics. As of early January 2024, the company ceased operations after its bankruptcy filing was converted to Chapter 7 liquidation.
4 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Predictive Technology Group, Inc..